Parkinson's and Alzheimer's diagnoses are increasing as populations age, yet neurological trials face some of the toughest operational challenges in clinical research. Slow disease progression means that many trials run for years, creating a patient retention problem in a population already managing mobility limitations and cognitive decline. Continuous monitoring offers a way to ease the burden of neurological trials by enabling hybrid and decentralized trial designs, supplying objective data between clinical visits, and reducing how often patients need to travel to a site. This gives trial teams a way to support neurological drug development without asking more of an already vulnerable patient population.
In this blog, we will cover:
For a patient managing Parkinson's tremors or early-stage Alzheimer's, a single site visit can mean coordinating transportation, arranging caregiver support, and enduring a physically demanding day, all for a study that may run for several years. Multiply that across dozens of visits over the life of a trial, and it's easy to see why neurological trials see higher dropout rates than many other therapeutic areas. Every missed or rescheduled visit is a gap in the data and a risk to the trial's statistical power.
Hybrid and decentralized trial designs reduce that burden by replacing some in-person visits with at-home monitoring. A continuous wearable can track vitals between scheduled assessments so that the clinical team isn't dependent on the patient making it to the site to know whether something has changed. Patients stay enrolled longer because the trial asks less of them physically, and sponsors get a more complete dataset because the gaps between visits are no longer blind spots.
Much of the data collected in neurological trials depends on subjective clinical assessment rather than a lab value or scan. Tools like the Unified Parkinson's Disease Rating Scale or the Alzheimer's Disease Assessment Scale–Cognitive Subscale have a clinician score a patient's symptoms at scheduled visits. Those scores can be subjective because they vary depending on the clinician administering them, the patient's condition that day, or even the time of day the assessment takes place. These tools remain essential for measuring disease progression, but they only capture a patient’s status every few weeks or months, leaving long stretches of time where the trial has no visibility into the patient’s condition.
Continuous monitoring doesn't replace these clinical assessments, but it fills the space between them with objective data that doesn't depend on anyone's interpretation. A meaningful shift in heart rate variability, resting heart rate, or activity level can signal that something has changed in a patient's condition well before the next scheduled visit catches it. For trial teams working with endpoints that are inherently variable and infrequent, that continuous layer of vitals data offers a steadier, more complete picture of what's happening with each patient over the full course of the study.
As neurological drug development continues to grow, trial teams that build continuous data collection into their protocols from the start will be better positioned to retain patients and capture a fuller picture of how treatments perform over time. Vivalink partners with sponsors and CROs to bring continuous, multi-vital monitoring into neurological trials, whether that means supplementing site visits or supporting a fully decentralized model. Reach out to learn how our wearable devices can fit into your next protocol.